Side by side
Liraglutide vs Tesamorelin
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Liraglutide | Tesamorelin | |
|---|---|---|
| What it is | The first GLP-1 analogue approved for weight loss. A daily injection, superseded by weekly semaglutide but still the best-documented compound in the class. | A GHRH analogue approved by the FDA for reducing excess visceral fat in HIV-associated lipodystrophy. The only compound in this category with completed phase 3 trials. |
| EvidenceHow much human evidence exists, not how well it works. | Approved | Approved for another indication |
| Regulatory statusReviewed 2026-08-16 | Approved by the FDA and EMA. Marketed as Victoza for type 2 diabetes and as Saxenda for chronic weight management at a higher dose. Both carry a boxed warning about thyroid C-cell tumours. Compounded or research-chemical liraglutide is not the approved product and has not been through the manufacturing controls the approval rests on. | Approved by the FDA as a prescription medicine for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for body composition, athletic performance or anti-ageing use, and material sold as a research chemical is not the approved product. |
| Routes | Subcutaneous | Subcutaneous |
| Half-life | 13 hours | 0.4 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | Not recorded | $2.35/mg |
| Median per mg | Not recorded | $7.00/mg |
| Vendors with a price | Not recorded | 49 |
| Storage once mixed | After first use, up to 30 days at room temperature below 30 °C or refrigerated. Protect from light and do not freeze. | Refrigerated at 2–8 °C. The approved product is intended for use shortly after reconstitution rather than stored for weeks. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.